Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Xylometazoline · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Xylometazoline | DRUG | - |
Inclusion Criteria: * Over 18 years * Have had moderate common cold symptoms for less than 36 hours. Exclusion Criteria: * Congested/runny nose for more than two continuous weeks in the previous 12 months * Deviated septum or nasal polyps * Recent use of antibiotics * Recent sinusitis Other prot...
Xylometazoline is used for the common cold, where it acts as a nasal decongestant. It is a small molecule developed by Novartis AG under the ticker NVS. A Phase 3 trial studied its decongestant effect, timing of effect, and impact on sleep and general well-being in adults with a common cold.
Xylometazoline is an agonist at the alpha-adrenergic receptors ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, and ADRA2C. By activating these receptors it produces a decongestant effect, which is the basis for its use in the common cold. It is a small molecule in the infectious disease therapeutic area.
Novartis AG, which trades under the ticker NVS, is the developer of xylometazoline. The company ran the Phase 3 clinical program evaluating the drug in subjects with a common cold.
Xylometazoline is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The drug is investigational and is not described as approved by the FDA.
Xylometazoline has been studied in one Phase 3 trial, NCT00452270, titled Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold. That trial is completed, enrolled 60 participants, was randomized and double blind, and was conducted in the United Kingdom.